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The interaction of the urokinase-type plasminogen activator (uPA) receptor (uPAR) with integrins plays a critical
role in the regulation of cell adhesion and migration. However, the molecular events underlying the modulation of
the interaction of uPAR and integrin are poorly understood. Gangliosides are thought to regulate epithelial cell
adhesion and migration by inhibiting a5b1 integrin and epidermal growth factor receptor (EGFR) signaling. We
report here that increases in the expression of ganglioside NeuAca2 ! 3Galb1 ! 3GalNAcb1 ! 4(NeuAca2 !
8NeuAca2 ! 3)Galb1 ! 4Glcb1-Cer (GT1b) or NeuAca2 ! 3Galb1 ! 4Glcb1-Cer (GM3) inhibit uPA-dependent cell
migration by preventing the association of uPAR with a5b1 integrin or uPAR/a5b1 integrin with the EGFR, respec-
tively. As a result, uPA-dependent focal adhesion kinase (FAK) and integrin-mediated EGFR signaling are sup-
pressed. Both gangliosides inhibit uPAR signaling-stimulated migration; however, GM3 inhibits uPA-induced
EGFR phosphorylation by blocking the crosstalk between integrin and EGFR, whereas GT1b suppresses both uPA-
induced FAK and EGFR activation by preventing the activation of integrin a5b1.
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Epithelial cell motility plays a fundamental role in both
physiologic and pathologic conditions, such as tissue re-
sorption and remodeling during embryogenesis, wound
healing, and metastasis of carcinomas. The mechanisms
involved in the modulation of cell motility, however, are
poorly understood, especially at the membrane level. The
coordinated expression and function of adhesion receptors
(particularly integrins) and of the protease systems that
counteract cell–substratum and cell–cell interactions play a
critical role. One of these protease systems, the plasmino-
gen activation system, is comprised of plasminogen, the
plasminogen activators (urokinase-type plasminogen acti-
vator (uPA) and tissue-type plasminogen activator), their
respective cell surface receptors, and their inhibitors (Chap-
man, 1997). The uPA receptor (uPAR), a glycosylpho-
sphatidylinositol (GPI)-anchored glycoprotein located in
the outer leaflet of the plasma membrane, has been shown
to initiate signal transduction events and affects cell prolif-
eration, adhesion, migration, and invasion (Chapman, 1997;
Xue et al, 1997; Aguirre Ghiso et al, 1999; Ossowski et al,
1999; Andreasen et al, 2000; Ossowski and Aguirre-Ghiso,
2000; Aguirre-Ghiso et al, 2001; Ma et al, 2001; Jo et al,
2002). As such, uPAR signaling is thought to participate in
cell migration during development, wound healing, vascular
remodeling, and cancer cell metastasis and invasion. The
activation and/or expression of uPAR on cells strongly cor-
relate with their migratory and invasive potential (Ossowski
et al, 1991; Aguirre Ghiso et al, 1999), and are able to be
modulated by several factors, including growth factors (ep-
idermal growth factor (EGF), transforming growth factor-b,
etc.), cytokines (interleukin-1, interleukin-8, etc.), and matrix
molecules, particularly vitronectin (Wei et al, 1994; Yebra
et al, 1999; Sandberg et al, 2001; Shiratsuchi et al, 2002;
Unlu and Leake, 2003). uPAR is also able to trigger activa-
tion of several signaling pathways and thus to modulate cell
adhesion and migration indirectly, such as via activation of
a5b1 integrin and focal adhesion kinase (FAK) signaling
when cells grow on a fibronectin matrix (Yebra et al, 1999;
Aguirre Ghiso, 2002).
Lacking both transmembrane and intracytoplasmic do-
mains (Ploug et al, 1991), uPAR-modulated signaling trans-
duction is thought to require transmembrane adaptors
(Resnati et al, 1996), particularly integrins (Wei et al, 1996;
Tarui et al, 2001, 2003; Kugler et al, 2003), and EGF receptor
Abbreviations: EGFR, epidermal growth factor receptor; FAK, focal
adhesion kinase; GD2, GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2 !
3)Galb1 ! 4Glcb1-Cer; GD3, NeuAca2 ! 8NeuAca2 ! 3Galb1
! 4Glcb1-Cer; GM2, GalNAcb1 ! 4(NeuAca2 ! 3)Gal b1 !
4Glcb1-Cer; GM3, NeuAca2 ! 3Galb1 ! 4Glcb1-Cer; GPI, gly-
cosylphosphatidylinositol; GT1b, NeuAca2 ! 3Galb1 ! 3GalNAcb1
! 4(NeuAca2 ! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-Cer; PPPP,
threo-1-phenyl-2-hexadecanoyl-amino-3-pyrrolidinopropan-1-ol HCl;
RU-486, mifepristone; SDS-PAGE, sodium dodecylsulfate-polya-
crylamide gel electrophoresis; TLC, thin-layer chromatography;
uPA, urokinase-type plasminogen activator; uPAR, urokinase-type
plasminogen activator receptor
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(EGFR) (Liu et al, 2002; Jo et al, 2003). uPAR has been
shown to associate with integrins based on co-immuno-
precipitation, co-immunolocalization, and resonance energy
transfer studies (Xue et al, 1994, 1997; Wei et al, 1996;
Kugler et al, 2003). uPAR may also act as the primary ligand
for a5b1 integrin upon uPA-induced cell adhesion and mi-
gration (Tarui et al, 2001, 2003; Kugler et al, 2003). In this
way, uPA/uPAR signal transduction is initiated through
binding to functional a5b1 integrin. uPAR also appears to
form a complex with EGFR to facilitate EGFR signaling, thus
activating several kinases, including mitogen-activated pro-
tein kinases, phosphatidylinositol-3-kinase, and Src kin-
ases. Through its effect on EGFR signaling, uPA is able to
modulate cell proliferation, adhesion, migration, invasion,
and survival (Della Rocca et al, 1997, 1999; Prenzel et al,
2001; Liu et al, 2002). The mechanism of the role of trans-
membrane receptors, including integrin and EGFR, in uPA/
uPAR signaling is not fully established.
Gangliosides, sialylated glycosphingolipids that are lo-
cated on the outer leaflet of the plasma cell membrane, are
thought to participate in the regulation of several biological
processes, including cell proliferation, adhesion, migration,
differentiation, and apoptosis (Paller et al, 1995; Sung et al,
1998; Wang et al, 2001a, b, c, 2002a, b, 2003a; Sun et al,
2002). Gangliosides are distinguished from one another by
the extent and location of their sialic acid residues, as well
as by their carbohydrate structure linked to a ceramide
core. Our studies have shown that NeuAca2 ! 3Galb1 !
4Glcb1-Cer (GM3), the predominant ganglioside of epithelial
cells (Wang et al, 2001b), interacts directly with EGFR
(Wang et al, 2001d) and inhibits both ligand-dependent and
ligand-independent activation of EGFR (Wang et al, 2001a,
d, 2002a, 2003a), thus inhibiting cell proliferation (Wang
et al, 2001a, 2003a), migration, and invasion (Wang et al,
2003b). The highly sialylated ganglioside, NeuAca2 !
3Galb1 ! 3GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2 ! 3)
Galb1 ! 4Glcb1-Cer (GT1b), strongly inhibits adhesion,
spreading, and migration of cultured epithelial cells, spe-
cifically when cells are plated on a fibronectin matrix (Paller
et al, 1995; Sung et al, 1998; Wang et al, 2001b, 2002b).
GT1b binds directly to the a5 subunit of a5b1 integrin (Wang
et al, 2001b) and inhibits its activation and downstream
signaling, including FAK, c-Src, phosphatidylinositol-3-kin-
ase (Wang et al, 2002b), Ras,1 and integrin-linked kinase
(Wang et al, 2001c), to prevent cell adhesion, impair motility
(Paller et al, 1995; Wang et al, 2001b, 2002b), and trigger
cell apoptosis (Wang et al, 2001c).
We have evaluated the effects of endogenous and ex-
ogenous modulation of gangliosides GT1b and GM3 on the
motility of squamous carcinoma cells, and have addressed
the possibility that ganglioside expression modulates uPAR
signaling. These studies show that alterations in GT1b and
GM3 expression differentially affect uPAR-directed signa-
ling in this carcinoma cell line at the membrane level. GT1b
modulates the ability of uPAR to form a complex with a5b1
integrin and thereby prevents the activation of a5b1 integrin
in the face of uPA, which results in the disassociation of
uPAR/a5b1 integrin with EGFR, whereas GM3 regulates the
crosstalk of uPAR/a5b1 integrin with EGFR. Although both
gangliosides inhibit uPA-induced cell migration, GT1b pre-
vents uPAR signaling-directed FAK and EGFR activation
and totally inhibits cell migration in the face of uPA, whereas
GM3 inhibits uPAR signaling-stimulated EGFR phosphor-
ylation and only partially reverses cell migration in the face
of uPA.
Results
Ganglioside modulation regulates cell migration We
have used a variety of genetic and biochemical manipula-
tions to change specific ganglioside expression in SCC12
squamous carcinoma cells (Fig 1, Table I). When the ex-
pression of ganglioside is manipulated, a significant differ-
ence in migration is first noted within 12 h of culture in the
face of uPA (Fig 2). Ganglioside depletion by either threo-
1-phenyl-2-hexadecanoyl-amino-3-pyrrolidinopropan-1-ol
HCl (PPPP) treatment (Fig 2A, the 3rd bar, po0.001) or si-
alidase overexpression (Fig 2B, the 3rd bar, po0.001) leads
to a 3.1–3.8-fold increase in cell migration by both scratch
assay (not shown) and chemotaxis migration assay (Fig 2) in
Figure1
Endogenous modulation of gangliosides NeuAca2 ! 3Galb1 !
4Glcb1-Cer (GM3) and NeuAca2 ! 3Galb1 ! 3GalNAcb1 ! 4(Ne-
uAca2 ! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-Cer (GT1b) expression.
Overexpression of a human plasma ganglioside-specific sialidase de-
pletes functional gangliosides by cleaving sialic acid residue(s) from
gangliosides (A). Incubation of SCC12 cells with threo-1-phenyl-2-hex-
adecanoyl-amino-3-pyrrolidinopropan-1-ol HCl (PPPP) to deplete GM3
and downstream gangliosides, such as GT1b (B). Treatment with an-
tisense oligodeoxynucleotides to both GalNAcb1 ! 4(NeuAca2 !
3)Gal b1 ! 4Glcb1-Cer (GM2)/GD2 synthase and NeuAca2 !
8NeuAca2 ! 3Galb1 ! 4Glcb1-Cer (GD3) synthase prevents the syn-
thesis of downstream ganglioside components GM2 and GD3, respec-
tively, leading to endogenous overexpression of GM3 (C). Stable
transfection of cells with a human GM2/GD2 synthase cDNA in an
inducible system and induction with mifepristone (RU-486) as de-
scribed (Wang et al, 2002b) induces GT1b overexpression in SCC12
cells (D).
1Wang XQ, Sun P, Paller AS: Ganglioside modulated keratin-
ocyte adhesion, spreading and migration by both integrin-and
EGFR-mediated signaling pathways. J Invest Dermatol 117:474,
2001 (abstr).
840 WANG ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
comparison with dimethyl sulfoxide (DMSO) vehicle-treated
(A, the 2nd bar), pcDNA vector-transfected (B, the 2nd bar),
or untreated parental SCC12 (the 1st bars of A and B) con-
trols. In the absence of uPA, migration does not occur, de-
spite depletion of ganglioside (bars on the right side of
Fig 2A–F).
Increases in GT1b expression by either overexpression
of GalNAcb1 ! 4(NeuAca2 ! 3)Gal b1 ! 4Glcb1-Cer
(GM2)/GD2 synthase (Fig 2C, the 4th bar) or pharmacolog-
ical addition of purified GT1b (Fig 2D, the 5th bar) inhibit
uPA-dependent cell migration by 2.5–2.6-fold in compari-
son with p17x4-GLVP mock vector control (C, the 2nd bar),
the GM2/GD2 synthase cDNA-transfected cells without RU-
486 induction (C, the 3rd bar), DMSO vehicle-treated cells
(D, the 2nd bar), cells with increased control ganglioside
GM2 (D, the 3rd bar), and parental SCC12 cell (the 1st bars
of C and D) controls (po0.01). Even in the absence of GM3,
increases in GT1b expression dramatically decrease uPA-
dependent cell migration (Fig 2E, the 4th bar) in comparison
with cells depleted of both GM3 and GT1b (E, the 1st bar)
and cells depleted of both GM3 and GT1b but treated with
control ganglioside GM2 (E, the 2nd bar) (po0.001). When
both GM3 and GT1b are overexpressed by treating cells
with antisense oligodeoxynucleotides to both GM2/GD2
synthase and NeuAca2 ! 8NeuAca2 ! 3Galb1 ! 4Glcb1-
Cer (GD3) synthase (GM3 " , GT1b # ), but the deficient
GT1b is ‘‘rescued’’ pharmacologically (GM3 " , GT1b " ),
cell migration is inhibited by 6.6-fold (Fig 2F, the 3rd bar) in
comparison with antisense oligodeoxynucleotides-treated
cells without GT1b ‘‘rescue’’ (Fig 2F, the 1st bar) or anti-
sense oligodeoxynucleotides-treated cells incubated with
control ganglioside GM2 (F, the 2nd bar) (po0.001). When
GT1b is overexpressed, the migration of cells in the ab-
sence of GM3 (Fig 2E, the 4th bar) is similar to that of cells in
the presence of GM3 (Fig 2D, the 4th bar) and of cells that
overexpress GM3 as well (Fig 2F, the 3rd bar).
Increased GM3 expression by pharmacological addition
of purified GM3 (Fig 2D, the 4th bar) also inhibits cell mi-
gration by 1.8-fold in comparison with cells treated without
(D, the 1st bar) or with either DMSO vehicle control (D, the
2nd bar) or control ganglioside GM2 (D, the 3rd bar)
(po0.05). In the absence of GT1b, pharmacologic addition
of GM3 inhibits cell migration by 1.9-fold (Fig 2E, the 3rd
bar) in comparison with cells depleted of both GM3 and
GT1b by PPPP treatment (E, the 1st bar), regardless of
treatment with control ganglioside GM2 (E, the 2nd bar)
(po0.05).
Modulation of GT1b expression affects the association
of uPAR with both a5b1 integrin and EGFR Depletion of
GM3 and GT1b by either sialidase overexpression (Fig 3A,
lanes 3 and 4, middle and bottom rows) or PPPP treatment
(Fig 3C, lane 3, middle and bottom rows) increases the as-
sociation of both a5b1 integrin and EGFR with uPAR in
comparison with parental SCC12 cells (Fig 3A and C, lane
1), pcDNA vector-treated cells (Fig 3A, lane 2), or DMSO
vehicle-treated cells (Fig 3C, lane 2). In the absence of
GT1b, GM3 overexpression by antisense oligodeoxynuc-
Table I. Results of ganglioside modulation (Wang et al, 2001c, 2002a, b; Sun et al, 2002)
Cell line or treatment
Ganglioside
expression
Control(s) (ganglioside expression of parental
SCC12 cells)
SCC12 cells transfected with plasma ganglioside-
specific sialidase cDNA (‘‘SSIA’’)
GM3 ## GT1b ## Vector transfection (pcDNA)
SCC12 cells treated with PPPP GM3 ## GT1b ## Vehicle (DMSO)-treated cells
SCC12 cells treated with oligodeoxynucleotides
directed against both GM2/GD2 synthase and GD3
synthase
GM3 "" GT1b ## Sense oligodeoxynucleotides to both GM2/GD2
synthase and GD3 synthase
SCC12 cells treated with purified GM3 GM3 "" Vehicle (DMSO)-treated cells
Ganglioside GM2-treated cells
SCC12 cells treated with PPPP and ‘‘rescued’’ with
purified GM3
GM3 "" GT1b ## SCC12 cells treated with PPPP and ‘‘rescued’’ with
control ganglioside GM2
SCC12 cells treated with PPPP and ‘‘rescued’’ with
purified GT1b
GM3 ## GT1b ""
SCC12 cells transfected with GM2/GD2 synthase gene
and induced with RU486
GT1b "" Vector transfection (p17x4-GLVP)
GM2/GD2 synthase transfection without RU486
induction
SCC12 cells treated with purified GT1b GT1b "" Vehicle (DMSO) treated cells
Ganglioside GM2-treated cells
SCC12 cells treated with oligodeoxynucleotides
directed against both GM2/GD2 synthase and GD3
synthase, ‘‘rescued’’ with purified GT1b
GM3 "" GT1b "" SCC12 cells treated with oligodeoxynucleotides
directed against both GM2/GD2 synthase and GD3
synthase, ‘‘rescued’’ with control ganglioside GM2
PPPP, threo-1-phenyl-2-hexadecanoyl-amino-3-pyrrolidinopropan-1-ol HCl; DMSO, dimethyl sulfoxide; GM3, NeuAca2 ! 3Galb1 ! 4Glcb1-Cer;
GT1b, NeuAca2 ! 3Galb1 ! 3GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-Cer; GLVP, N=terminal VP16 transcriptional activation
domain fused to a yeast GAL4 DNA binding domain; GM2, GalNAcb1 ! 4(NeuAca2 ! 3)Gal b1 ! 4Glcb1-Cer; GD2, GalNAcb1 ! 4(NeuAca2
! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-Cer.
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leotide treatment (Fig 3A, lane 6, middle and bottom rows)
or pharmacological addition of GM3 to PPPP-treated cells
(Fig 3C, lane 4, middle and bottom rows) leads to abrogation
of the association of uPAR with EGFR, but increases the
association of uPAR with a5b1 integrin, in comparison with
sense oligodeoxynucleotide-treated (A, lane 5), DMSO ve-
hicle-treated (C, lane 2), or untreated parental SCC12 (A
and C, lane 1) controls. In the presence of GT1b, GM3
overexpression by pharmacological addition of purified
GM3 into SCC12 cells only blocks the association of EGFR
with uPAR, without stimulating the association of a5b1 in-
tegrin with uPAR (Fig 3A, lane 14, middle and bottom rows)
in comparison with cells treated without (lane 11) or with
either DMSO vehicle (lane 12) or ganglioside GM2 (lane 13)
controls. Regardless of the expression of GM3, GT1b over-
expression by the increased expression of GM2/GD2 synt-
hase (Fig 3A, lanes 9 and 10) or pharmacological addition of
purified GT1b (Fig 3A, lane 15; Fig 3B, lanes 4–6; Fig 3C,
lane 5) disrupts the association of uPAR with a5b1 integrin
(middle rows), as well as the association of uPAR with the
EGFR (bottom rows) in comparison with controls (Fig 3A,
lanes 1,7, 8, and 11–13; Fig 3B, lanes 1–3; Fig 3C, lanes
1–3). Modulation of ganglioside expression does not affect
the expression of uPAR, a5b1 integrin (not shown), or EGFR
(Fig 4A, top row).
Ganglioside modulation regulates uPA-stimulated
EGFR and FAK phosphorylation In the presence of
uPA, depletion of gangliosides GT1b and GM3 by sialidase
overexpression facilitates uPA-stimulated EGFR and FAK
phosphorylation (Fig 4A and B, lane 6, bottom rows) in
comparison with mock vector transfected cell (lane 4) and
parental SCC12 cell (lane 2) controls. Depletion of GT1b in
the face of increased GM3 by antisense oligodeoxynucleo-
tide treatment stimulates uPA-induced FAK phosphorylation
(Fig 4B, lane 10, bottom row), but uPA-induced EGFR phos-
phorylation is prevented (Fig 4A, lane 10, bottom row).
Ganglioside GT1b overexpression via upregulating GM2/
GD2 synthase expression inhibits uPA-induced phosphor-
ylation of both EGFR and FAK (Fig 4A and B, lane 16, bot-
tom rows). In the absence of uPA (lanes 1, 3, 5, 7, 9, 11, 13,
and 15), neither expression (top row) nor phosphorylation
(bottom row) of EGFR (A) and FAK (B) is affected by the
modulation of ganglioside expression. Ganglioside modu-
lation has no effect on the expression of either EGFR or
FAK, regardless of the absence or presence of uPA (Fig 4A
and B, top rows).
Prevention of cell migration by gangliosides requires
the inhibition of both FAK and EGFR kinase activi-
ties Inhibition of EGFR kinase activity with AG1478 or of
Figure 2
Ganglioside modulation regulates urokinase-
type plasminogen activator- (uPA-) depend-
ent cell migration. Cell migration was per-
formed by both scratch assay (not shown) and
chemotaxis migration assay using a Transwell
system (BD Biosciences, Bedford, Massachu-
setts). After starvation of serum and growth fac-
tors, cells prepared as indicated below were
stimulated with (þ ) or without () 10 nM of
uPA. (A) Treatment with threo-1-phenyl-2-
hexadecanoyl-amino-3-pyrrolidinopropan-1-ol
HCl (PPPP) (NeuAca2 ! 3Galb1 ! 4Glcb1-
Cer (GM3) and NeuAca2 ! 3Galb1 !
3GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2 ! 3)
Galb1 ! 4Glcb1-Cer (GT1b) # ); untreated
SCC12 cells (lanes 1, 4); treated with dimethyl
sulfoxide (lanes 2, 5); treated with PPPP (lanes 3,
6). (B) Stable transfection of SCC12 cells with
human plasma ganglioside-specific sialidase
(SSIA) (GM3 and GT1b # ); SCC12 cells (lanes
1, 4); pcDNA mock transfected cells (lanes 2, 5);
SSIA cells (lanes 3, 6). (C) Stable transfection of
SCC12 cells with GalNAcb1 ! 4(NeuAca2 ! 3)
Gal b1 ! 4Glcb1-Cer (GM2)/GalNAcb1 !
4(NeuAca2 ! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-
Cer (GD2) synthase and with mifepristone (RU-
486) induction (GT1b " ). Parental SCC12 cells
(lanes 1, 5); p17x4-GLVP vector-transfected cells
(lanes 2, 6); GM2/GD2 synthase gene-trans-
fected cells without RU-486 induction (lanes 3,
7); GM2/GD2 synthase gene transfected cells with 100 nM RU-486 induction: (lanes 4, 8). (D) SCC12 cells treated with specific purified ganglioside.
Parental SCC12 cells (lanes 1, 6); DMSO vehicle (lanes 2, 7); 50 mM GM2 (lanes 3, 8); 50 mM GM3 (lanes 4, 9); 1mM GT1b (lanes 5, 10). (E) PPPP-
treated (ganglioside-depleted) SCC12 cells, incubated with specific purified ganglioside to ‘‘rescue’’ the specific ganglioside expression. SCC12
cells treated with PPPP alone (lanes 1, 5); þ 50 mM GM2 (lanes 2, 6); þ 50 mM GM3 (lanes 3, 7);þ 1mM GT1b (lanes 4, 8). (F) SCC12 cells treated with
antisense oligodeoxynucleotides to both GM2/GD2 synthase and NeuAca2 ! 8NeuAca2 ! 3Galb1 ! 4Glcb1-Cer (GD3) synthase (increased
GM3), incubated with purified ganglioside to ‘‘rescue’’ the specific ganglioside expression. SCC12 cells treated with antisense oligodeoxynuc-
leotides alone (GM3 " and GT1b # ) (lanes 1, 4); þ50 mM GM2 (lanes 2, 5); þ1mM GT1b (GM3 " and GT1b " ) (lanes 3, 6). Migration was
determined with a Transwell unit as indicated in Materials and Methods. The extent of migration for each cell type was determined by optical density
readings at 560 nm, and expressed in comparison with SCC12 parental cells as mean percentages  SD. Studies were performed at least three
different times in duplicate. The data shown represent the mean values of 4 SSIA cell clones (SSIA3, SSIA6, SSIA12, and SSIA25), 4 GM2/GD2
synthase overexpressing clones (C-1, -5, -11, and -26), or two mock controls from each group, pcDNA (clones 1 and 3) as SSIA cell controls; p17x4-
GLVP (clones 3 and 6) as controls for GM2/GD2 synthase transfection.
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FAK function with FAK antisense oligodeoxynucleotide
partially reverses the stimulatory effects of ganglioside
depletion on uPA-dependent cell migration (Fig 5)
(AG1478-treated vs untreated, po0.05; FAK antisense
oligodeoxynucleotide treated vs untreated, po0.01). Treat-
ment with both inhibitors in combination prevents the stim-
ulation of uPA-induced cell migration in cells depleted of
gangliosides GT1b and GM3 by sialidase overexpression
(Fig 5B) (AG1478þFAK antisense oligodeoxynucleotide-
treated vs untreated, po0.001). The migration of cells
treated with 0.1% DMSO (control for AG1478 application) or
FAK sense oligodeoxynucleotide resembles that of untreat-
ed cells (not shown). The extent of cell migration of cells
grown in serum-free medium without uPA stimulation is
similar to that of cells in which EGFR and FAK signaling is
inhibited (not shown).
Discussion
In this report, we have manipulated the expression of gang-
liosides GT1b and GM3 through both genetic and biochem-
ical means and have studied the specific effects of each
ganglioside on uPA-induced migration of SCC12 cells. We
have shown that increases in membrane GM3 and GT1b
both inhibit uPA-induced cell migration, but that GT1b ap-
pears to have a more profound influence. These data sug-
gest that GT1b affects uPA-induced migration at an earlier
step than GM3 does. By investigating the mechanism of
these actions of gangliosides, we demonstrate distinct roles
of gangliosides GT1b and GM3 in regulating uPA-induced
motility of squamous carcinoma cells. GT1b prevents the
ability of uPAR to complex with a5b1 integrin and subse-
quently with EGFR, whereas GM3 only inhibits the associ-
ation of the uPAR/a5b1 integrin complex with EGFR. Thus,
GT1b is able to block the direct signaling of uPAR through
a5b1 integrin and FAK, as well as EGFR, whereas GM3 is
only able to prevent the contribution of EGFR signaling to
uPA-induced cell migration (Fig 6). These results further
suggest that the formation of an association of uPAR with
a5b1 integrin is vital for crosstalk of EGFR with a5b1 integrin
in cells exposed to uPA.
The downstream effects of GT1b and GM3 on inhibiting
FAK phosphorylation and EGFR phosphorylation are con-
Figure 3
Alteration of NeuAca2 ! 3Galb1 !
3GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2
! 3)Galb1 ! 4Glcb1-Cer (GT1b) ex-
pression regulates the association of
urokinase-type plasminogen activator
receptor (uPAR) with both a5b1 integrin
and epidermal growth factor receptor
(EGFR). Cells were prepared as de-
scribed in Materials and Methods and in
Fig 2. After starvation of both growth fac-
tors and serum, cells were stimulated with
10 nM urokinase-type plasminogen acti-
vator (uPA) for 10 min, and uPAR was
immunoprecipitated from cells as de-
scribed in Materials and Methods. One-
third of the resulting immunoprecipitate
was treated with undenatured Laemmli
buffer for 30 min at room temperature and
applied to a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-
PAGE) mini-gel for immunoblotting with
anti-uPAR antibody to ensure equal load-
ing (top); the other two-thirds of each
immunoprecipitate was boiled in Laemmli
buffer for 10 min, and applied to an 8%
SDS-PAGE mini-gel for immunoblotting
with antibodies directed against a5b1 in-
tegrin (middle) or EGFR (bottom). (A)
(lanes 1 and 11) SCC12 cells; (lane 2)
pcDNA vector transfected cells; (lanes 3
and 4) SSIA cells, clones 3 and 6 (Ne-
uAca2 ! 3Galb1 ! 4Glcb1-Cer (GM3 # )
and GT1b # ), respectively; (lane 5)
SCC12 cells treated with sense oligo-
deoxynucleotides to both GalNAcb1 ! 4(NeuAca2 ! 3)Gal b1 ! 4Glcb1-Cer (GM2)/GalNAcb1 ! 4(NeuAca2 ! 8NeuAca2 ! 3)Galb1 ! 4Glcb1-
Cer (GD2) synthase and NeuAca2 ! 8NeuAca2 ! 3Galb1 ! 4Glcb1-Cer (GD3) synthase; (lane 6) SCC12 cells treated with antisense
oligodeoxynucleotides to both GM2/GD2 synthase and GD3 synthase (GM3 " and GT1b # ); (lane 7) p17x4-GLVP vector transfected cells; (lane
8) GM2/GD2 synthase cDNA transfected cells without RU-486 induction; (lanes 9 and 10) GM2/GD2 synthase overexpressing cells, clones 1 and 26
(GT1b " ); (lane 12) DMSO vehicle-treated SCC12 cells; (lane 13-15) SCC12 cells treated with GM2; (lane 13, GM2 " ), GM3 (lane 14, GM3 " ), or
GT1b (lane 15, GT1b " ). (B) SCC12 cells were treated with or without either sense or antisense oligodeoxynucleotides to both GM2/GD2 synthase
and GD3 synthase and the depleted GT1b was ‘‘rescued’’ by treatment with 1 mM GT1b (GM3 " and GT1b " ; lanes 4–6) or, as control, with 50 mM
GM2 (GM3 " , GT1b # ; lanes 1–3) as described in Materials and Methods. (Lanes 1, 4) SCC12 cells; (lanes 2, 5) sense oligodeoxynucleotides-
treated SCC12 cells; (lanes 3, 6) antisense oligodeoxynucleotides-treated SCC12 cells; (C) After SCC12 cells were treated with racemic threo-1-
phenyl-2-hexadecanoyl-amino-3-pyrrolidinopropan-1-ol HCl (PPPP) to deplete gangliosides or with vehicle DMSO as a control, and then specific
ganglioside content was ‘‘rescued’’ by incubation with purified ganglioside GM3 or GT1b as described in Materials and Methods. (Lane 1) SCC12
cells; (lane 2) DMSO vehicle-treated SCC12 cells; (lanes 3–5) PPPP-treated SCC12 cells without added ganglioside (GM3 # and GT1b # ; lane 3) or
with either GM3 (GM3 " , GT1b # ; lane 4) or GT1b (GM3 # , GT1b " ; lane 5).
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sistent with the actions of GT1b and GM3 at the membrane
level; GT1b is able to block the phosphorylation of both FAK
and the EGFR, whereas GM3 solely inhibits EGFR phos-
phorylation. These effects of GT1b and GM3 are also com-
mensurate with the previously described inhibitory effects
of gangliosides on EGFR and FAK signaling in cells
when exposed to EGF or grown on a fibronectin matrix
(Wang et al, 2001a, 2002a, b, 2003a, b). Blockade of EGFR
signaling with AG1478 and of FAK signaling through intro-
duction of FAK antisense oligomers are each able to abro-
gate partially the cell migration induced by ganglioside
depletion, whereas the combination of blockade of both
EGFR and FAK signaling is able to block migration alto-
gether, reiterating the role of both FAK signaling by a5b1
integrin and EGFR signaling through crosstalk with a5b1 in-
tegrin to uPAR signaling-modulated cell migration. These
mechanisms likely play a role in the demonstrated ganglio-
side-induced inhibition of cell migration and tumor malig-
nancy (Kawamura et al, 2001; Watanabe et al, 2002; Wang
et al, 2003b).
The uPAR, as with other GPI-anchored proteins, tends to
be localized to lipid rafts, sphingolipid–cholesterol micro-
domains on the plasma membrane that concentrate signa-
ling molecules (Harder and Simons, 1997; Horejsi et al,
1999). Specifically, uPAR is found in plasma membrane in-
vaginations (caveolae) in association with caveolin-1 (Rot-
hberg et al, 1992; Chapman et al, 1999; Wei et al, 1999), a
Figure4
Ganglioside modulation regulates the
phosphorylation of both epidermal
growth factor (EGFR) and focal adhe-
sion kinase (FAK). Cells were prepared as
described in Material and Methods. EGFR
expression (top row of A) and FAK expres-
sion (top row of B) were detected with anti-
EGFR or anti-FAK monoclonal antibody
using total protein from the whole-cell
lysate. The phosphorylations of EGFR (bot-
tom row of A) and FAK (bottom row of B)
were detected with anti-phosphotyrosine
kinase antibody (PY20) using immunopre-
cipitated EGFR and FAK from the whole-
cell lysate.
Figure 5
The acceleration of cell migration by ganglioside depletion re-
quires both focal adhesion kinase (FAK) and epidermal growth
factor receptor (EGFR) kinase activities. (A) Parental SCC12 cells,
mock transfected (pcDNA vector transfected) SCC12 cells, or SSIA
cells were treated with both AG1478 and FAK antisense oligo-
deoxynucleotide, or either 250 nM AG1478 or FAK antisense
oligodeoxynucleotide as previously described (Wang et al, 2002b).
108 cells/well were plated onto eight-well cell culture plates and a
scratch was made to perform either scratch assay (A) or quantitative
scratch assay (B) as described in Materials and Methods (Wang et al,
2003b). Starved cells were incubated in Dulbecco’s Modified Eagle’s
Medium/F12 medium containing 10 nM uPA in the absence or presence
of inhibitors and/or FAK antisense oligodeoxynucleotide. Migrating
cells in the scratched area were counted after incubation for 12 h at
371C. The extent of migration was quantified as the total number of
cells per high-power field with five fields counted, and expressed as the
mean number of cells  SD. Bar¼ 65 mm.
Figure6
Proposed mechanism of ganglioside effects on urokinase-type
plasminogen activator receptor (uPAR) signaling. NeuAca2 !
3Galb1! 3GalNAcb1! 4(NeuAca2! 8NeuAca2! 3)Galb1! 4Glcb1-
Cer (GT1b) blocks the ability of uPAR to form an association with both
a5b1 integrin and the epidermal growth factor receptor (EGFR), thereby
blocking cell migration induced by uPAR through inhibition of both focal
adhesion kinase (FAK) signaling and, through crosstalk, of EGFR
signaling. NeuAca2 ! 3Galb1 ! 4Glcb1-Cer (GM3) affects the asso-
ciation of uPAR/a5b1 integrin with the EGFR and therefore blocks uPA-
induced EGFR signaling that requires crosstalk with uPAR/a5b1 integrin.
The inhibitory effects of overexpression of GT1b and GM3 on the ac-
tivation of phosphatidylinositol-3-kinase and Src kinase may also con-
tribute to the role of specific ganglioside on uPAR signaling-modulated
cell migration (Wang et al, 2001a, b).
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protein that is thought to regulate integrin clustering, a cen-
tral event in integrin activation (Wary et al, 1998). High levels
of expression of caveolin-1 enhance the integrin-dependent
cell spreading and migration in epithelial tumor cells that is
promoted by uPAR signaling activation (Chapman et al,
1999), suggesting that caveolin-1 is important for the asso-
ciation of uPAR with other membrane receptors and signa-
ling molecules.
Gangliosides are known to participate in the regulation
of cell signaling within lipid rafts (Simons and Ikonen, 1997;
Iwabuchi et al, 1998; Prinetti et al, 1999; Brown and London,
2000; Abrami et al, 2001; Brown et al, 2002) and/or cave-
olae (Parton, 1994; Abrami et al, 2001) by associating with
signaling proteins, such as Src family kinases (Kasahara
et al, 1997; Kalka et al, 2001; Wang et al, 2002b), Ras (Par-
mryd et al, 2003), EGFR (Wang et al, 2002a), phosphatidy-
linositol-3-kinase (Wang et al, 2002b), integrin (Claas et al,
2001), and FAK (Iwabuchi et al, 2000; Wang et al, 2002b).
The demonstration in this study that gangliosides interfere
with the association of these receptors at the membrane
level suggests that gangliosides may interfere with the role
of caveolin-1 in organizing membrane receptors and signa-
ling elements. In fact, endogenous overexpression of spe-
cific gangliosides has previously been shown to modify the
composition of caveolar signaling domains. For example,
overexpression of ganglioside Galb1! 3GalNAcb1! 4(Ne-
uAca2! 3)Galb1! 4Glcb1-Cer (GM1) in Swiss 3T3 cells
inhibits platelet-derived growth factor receptor phosphoryl-
ation, and shifts this growth factor receptor from the
‘‘glycosphingolipid-enriched (GEM) domains’’ with cave-
olin-1 to the detergent-soluble ‘‘non-GEM’’ domains (Mi-
tsuda et al, 2002). Our previous studies have shown that
endogenous overexpression of GM3 shifts caveolin-1 itself
out of caveolar domains into proximity with the EGFR; given
the known inhibitory effect of caveolin-1 on EGFR signaling,
this shift could contribute to the inhibitory effect of GM3 on
EGFR activation (Wang et al, 2002a). This mechanism may
also explain the blockade of crosstalk between a5b1 integrin
and the EGFR by GM3 if it prevents the physical approx-
imation of the EGFR with a5b1 and uPAR in caveolin-1-rich
caveolar domains. The ability of GM3 to bind directly to the
EGFR (Wang et al, 2001d) and block its direct phosphor-
ylation (Wang et al, 2001a, 2002a, 2003a) may be an alter-
native explanation.
Our previous studies have not found any effect of gang-
liosides on the expression of signaling molecules, including
EGFR (Wang et al, 2001a, 2002a, 2003a), FAK (Wang et al,
2002b), integrin a5b1 (Wang et al, 2001b), and caveolin-1
(Wang et al, 2002a). Similarly, we have found no effect of
alteration in the expression of gangliosides on either the
expression of uPAR or the binding of uPAR with uPA (un-
published data). Our co-immunoprecipitation studies have,
however, shown the ability of overexpressed GT1b to as-
sociate with both a5b1 integrin and caveolin-1 in SCC12 cell
membrane (unpublished data). In contrast to its inhibitory
effect on EGFR signaling, caveolin-1 is known to promote
uPAR and a5b1 integrin signaling within the caveolar do-
main (Wei et al, 1999). Taken together, these data suggest
that the mechanism by which GT1b inhibits uPAR signaling
may involve either the direct binding of GT1b with a5b1
integrin (Wang et al, 2001b), which prevents the interaction
of a5b1 integrin with uPAR or disruption by GT1b of cave-
olin-1 promoted organization of uPAR, a5b1 integrin, and
FAK within the membrane.
Further investigation should be directed toward eluci-
dating the mechanisms by which specific gangliosides
affect uPAR signaling at the membrane level and the down-
stream signaling elements of uPAR that are impacted by
specific gangliosides. The demonstrated effects of gang-
lioside modulation on uPA-stimulated biologic processes
that impact wound healing, inflammatory responses, and
cancer metastasis will provide additional impetus to the
development of novel therapies that alter membrane gang-
lioside expression.
Materials and Methods
Cells The human keratinocyte-derived SCC12F2 cell line (SCC12),
a generous gift from Dr James Rheinwald (Harvard, Boston, MA),
was maintained in Dulbecco’s Modified Eagle’s Medium/F12
(DMEM/F12, 1:1, vol/vol) medium (Invitrogen, Carlsbad, California)
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
without antibiotics in 5% CO2 at 371C.
Ganglioside expression modulations Expression of ganglioside
was modulated by pharmacological addition of purified gang-
lioside, treatment with antisense oligodeoxynucleotides or a
chemical inhibitor, racemic PPPP (Matreya, Pleasant Gap,
Pennsylvania), or stable transfection of genes as a means to me-
tabolize or synthesize specific gangliosides (Table I and Fig 1).
Total depletion of membrane gangliosides Gangliosides were de-
pleted by either overexpression of a human plasma membrane
ganglioside-specific sialidase cDNA to inactivate cell membrane
gangliosides (Fig 1A) or treatment of cells with 2 mM of PPPP to
block the synthesis of gangliosides (Fig 1B). In brief, SCC12 cells
were stably transfected with the sialidase cDNA (GenBank acces-
sion number AB008185, courtesy of Dr T. Miyagi, Tokyo, Japan)
(Wada et al, 1999) in a pcDNA3 vector using LipofectAMINE re-
agent. Gene and protein expression in the resultant ‘‘SSIA cells’’
were demonstrated by northern blot and sialidase activity meas-
urements (Wang et al, 2001a; Sun et al, 2002). PPPP inhibits the
activity of glucosylceramide synthase, and thus prevents the for-
mation of glucosylceramide, a precursor for GM3. In contrast to 1-
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), PPPP
does not significantly increase ceramide content (Abe et al, 1995).
Ganglioside depletion was shown by thin-layer chromatography
(TLC) immunostaining (Wang et al, 2001b, d) and immunofluores-
cence microscopy (Wang et al, 2002a). Four SSIA cell lines (SSIA3,
SSIA6, SSIA12, and SSIA25), and two mock transfected pcDNA
cell lines were studied.
Overexpression of GM3 by treatment with either antisense oligo-
deoxynucleotides or pharmacological addition of puriﬁed GM3 The
cell membrane content of GM3 was endogenously increased as
described previously (Wang et al, 2002a) by treatment of SCC12
cells concurrently with antisense oligodeoxynucleotides of both
GM2/GD2 synthase and GD3 synthase, thereby blocking synthetic
pathways downstream of GM3 (Fig 1C). GM3 was also increased
by incubation of cells (pre-treated without or with PPPP) with 140
mM purified GM3 (Sigma, St Louis, Missouri) for 48 h in DMEM/F12
medium containing 2% FBS as described (Wang et al, 2001a, c,
2002b). Ganglioside expression was confirmed using ganglioside
ELISA (Wang et al, 2002b), TLC immunostaining (Wang et al,
2001b, d), and immunofluorescence microscopy (Wang et al,
2002a).
Overexpression of GT1b by either stable transfection of GM2/GD2
synthase or pharmacological addition of puriﬁed GT1b Because of
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anticipated inhibition of SCC12 cell proliferation and decreased cell
survival by overexpression of complex gangliosides, particularly
GT1b (Wang et al, 2001c), GM2/GD2 synthase cDNA (GenBank
accession number M83651, courtesy of Dr Lloyd, New York)
(Nagata et al, 1992) was introduced using an inducible expression
system (Wang et al, 1994, 1999) that utilizes anti-progestins as
inducers (Wang et al, 2002b) (Fig 1D). Although GM2/GD2 synt-
hase has the capability of driving both ‘‘a’’ pathway (to GM2) and
‘‘b’’ pathway (to GT1b) synthesis, our results showed that over-
expression of GM2/GD2 synthase only increases ‘‘b’’ pathway
ganglioside in SCC12 cells (Wang et al, 2002b). GT1b was also
increased by incubation of cells (pre-treated without or with either
PPPP or antisense oligodeoxynucleotides to both GM2/GD2 synt-
hase and GD3 synthase) with 1 mM of purified GT1b for 48h in
DMEM/F12 medium containing 2% FBS as described (Wang et al,
2001c). Gene expression was detected by northern blotting (Wang
et al, 2002b) and ganglioside expression was confirmed using
ganglioside ELISA (Wang et al, 2002b) and TLC immunostaining
(Wang et al, 2001b, d). Four GM2/GD2 synthase overexpressors
(C-1, -5, -11, and -26) and two mock transfected p17x4-tkA/
pCEP4 GL-VP (p17x4-GLVP) cell lines were used in the studies.
Cell migration assays Cell migration assays were performed us-
ing both chemotaxis migration assay (Transwell cell culture system,
Becton Dickinson, Indianapolis, Indiana) and scratch analysis. For
the chemotaxis migration assay, the Transwell inserts with a po-
lycarbonate filter of an 8 mm pore size were pre-coated with 20%
FBS on the underside only (Jo et al, 2003). After blockade of non-
specific binding sites with 0.5% bovine serum albumin (BSA) for
2 h at 371C, the insert was placed into a six-well cell culture plate,
and the lower portion of the plate was filled with 500 mL serum-free
DMEM/F12 medium containing 0.1% BSA and 10 nM uPA (Ca-
lbiochem, La Jolla, California). Starved SCC12 cells were pre-
treated with or without sense or antisense oligodeoxynucleotides
to both GM2/GD2 synthase and GD3 synthase; PPPP; or with pu-
rified ganglioside GM3, GT1b or, as a control ganglioside that does
not appear to affect SCC12 cell function, GM2 (50 mM) prior to
studies. SSIA cell lines, pcDNA3 vector mock transfected SCC12
cells, GM2/GD2 synthase overexpressors, or p17x4-GLVP vector
mock transfected SCC12 cells, treated with or without 100 nM of
RU-486 inducer for 36 h, were also assessed. These cells were
plated onto the upper surface of the filter. Cells were allowed to
migrate for 12 h at 371C in serum-free DMEM/F12 medium con-
taining 0.1% BSA with the continued addition of oligodeoxynuc-
leotides, with or without the RU-486 inducer, PPPP, or purified
gangliosides. Cells that migrated into the lower level of the six-well
cell culture plate were stained with crystal violet. Results were
presented as the mean  SD. The mean value was acquired by
comparing the optical density reading at 560 nm of cells treated
with purified gangliosides (GM3, GT1b, or GM2), PPPP, oligo-
deoxynucleotides, or gene transfected cells induced with or with-
out RU-486 with that of parental SCC12 cells.
To perform scratch assays, cells prepared as indicated above
were plated into an eight-well cell culture plate. Cells were allowed
to grow in 10% FBS containing DMEM/F12 medium for 4 h, and
then were washed with serum-free medium and starved of both
serum and growth factors overnight. A 1 mm wide scratch was
made across the cell layer using a pipette tip. DMEM/F12 medium
with or without 10 nM uPA was added into each well after washing
with serum-free medium twice. Plates were photographed after 6,
12, and 24 h. All experiments were performed at least six times.
Quantitative scratch assays were performed to study the effects
of kinase inhibitors on ganglioside-modulated changes in migra-
tion. Quantitative scratch assays were performed as described
above, except that a deep permanent gouge was made with a
razor blade into the culture plate at the border of the scratch to
allow definitive separation of migrating cells (Wang et al, 2003b).
Cells were treated without or with 250 nM AG1478 (EGFR kinase
inhibitor), or FAK antisense oligodeoxynucleotides (functional
blockade of FAK) as described before (Wang et al, 2002b). After
6, 12, and 24 h in culture, cells that had migrated into the scratched
area were identified and counted. Results were presented as the
mean  SD from five high-power fields per experiment in at least
four different experiments.
Incubation of cells with 0.1% DMSO solution was used as ve-
hicle controls for pharmacological addition of purified ganglioside
or inhibitor treatment studies; treatment of cells with FAK sense
oligodeoxynucleotides was used as a control for FAK antisense
oligodeoxynucleotide treatment.
Immunoblotting Immunoblotting was carried out as described
(Wang et al, 2001b, c) using either total protein from the whole-cell
lysate or immunoprecipitated protein, and an enhanced chemilu-
minescence detection system (Perkin-Elmer Life Sciences, Welles-
ley, Massachusetts). Monoclonal antibodies directed against
phosphotyrosine (PY20), EGFR, FAK (Transduction Laboratories,
Lexington Kentucky), a5b1 integrin, or uPAR (Santa Cruz Biotech.,
Inc. Santa Cruz, California) were applied for immunoblotting stud-
ies. If the total protein from the whole-cell lysate was applied for
immunoblotting, each blot was re-probed as previously described
(Wang et al, 2001c) with anti-actin antibody (Santa Cruz Biotech) to
confirm equal loading. All blots were repeated in at least three
different experiments. The 150 kDa undenatured whole IgG band,
55 kDa denatured heavy chain of the IgG band and, when detect-
able, the 25 kDa denatured light chain of the IgG band was cut
from the blots for figure presentation.
Immunoprecipitation Cells were prepared as indicated above
and stimulated with or without 10 nM uPA for 10 min after star-
vation of serum and EGF overnight. Cells were harvested, lysed
in cold immunoprecipitation buffer, and EGFR, FAK, or uPAR was
immunoprecipitated from cell lysates as previously described
(Wang et al, 2001b, c).
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